Interleukin-8 (IL-8) as a Potential Mediator of an Association between Trimethylamine N-Oxide (TMAO) and Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) among African Americans at Risk of Cardiovascular Disease
Abstract
:1. Introduction
2. Materials and Methods
3. Results
4. Discussion
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Baginski, A.; Farmer, N.; Baumer, Y.; Wallen, G.R.; Powell-Wiley, T. Interleukin-8 (IL-8) as a Potential Mediator of an Association between Trimethylamine N-Oxide (TMAO) and Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) among African-Americans at Risk for Cardiovascular Disease. FASEB J. 2022, 36. [Google Scholar] [CrossRef]
- Fennema, D.; Phillips, I.R.; Shephard, E.A. Trimethylamine and Trimethylamine N-Oxide, a Flavin-Containing Monooxygenase 3 (FMO3)-Mediated Host-Microbiome Metabolic Axis Implicated in Health and Disease. Drug Metab. Dispos. 2016, 44, 1839–1850. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zou, Q.; Bennion, B.J.; Daggett, V.; Murphy, K.P. The Molecular Mechanism of Stabilization of Proteins by TMAO and Its Ability to Counteract the Effects of Urea. J. Am. Chem. Soc. 2002, 124, 1192–1202. [Google Scholar] [CrossRef]
- Sarma, R.; Paul, S. Exploring the molecular mechanism of trimethylamine-N-oxide’s ability to counteract the protein denaturing effects of urea. J. Phys. Chem. B 2013, 117, 5691–5704. [Google Scholar] [CrossRef]
- Wang, Z.; Klipfell, E.; Bennett, B.J.; Koeth, R.; Levison, B.S.; Dugar, B.; Feldstein, A.E.; Britt, E.B.; Fu, X.; Chung, Y.M.; et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 2011, 472, 57–63. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Liu, Y.; Dai, M. Trimethylamine N-Oxide Generated by the Gut Microbiota Is Associated with Vascular Inflammation: New Insights into Atherosclerosis. Mediat. Inflamm. 2020, 2020, 4634172. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- He, Z.; Kwek, E.; Hao, W.; Zhu, H.; Liu, J.; Ma, K.Y.; Chen, Z.Y. Hawthorn fruit extract reduced trimethylamine-N-oxide (TMAO)-exacerbated atherogenesis in mice via anti-inflammation and anti-oxidation. Nutr. Metab. 2021, 18, 6. [Google Scholar] [CrossRef] [PubMed]
- Rath, S.; Heidrich, B.; Pieper, D.H.; Vital, M. Uncovering the trimethylamine-producing bacteria of the human gut. Microbiome 2017, 5, 54. [Google Scholar] [CrossRef] [Green Version]
- Mei, Z.; Chen, G.C.; Wang, Z.; Usyk, M.; Yu, B.; Baeza, Y.V.; Humphrey, G.; Benitez, R.S.; Li, J.; Williams-Nguyen, J.S.; et al. Dietary factors, gut microbiota, and serum trimethylamine-N-oxide associated with cardiovascular disease in the Hispanic Community Health Study/Study of Latinos. Am. J. Clin. Nutr. 2021, 113, 1503–1514. [Google Scholar] [CrossRef]
- Wang, B.; Qiu, J.; Lian, J.; Yang, X.; Zhou, J. Gut Metabolite Trimethylamine-N-Oxide in Atherosclerosis: From Mechanism to Therapy. Front. Cardiovasc. Med. 2021, 8, 723886. [Google Scholar] [CrossRef]
- Zhang, L.; Song, K.; Zhu, M.; Shi, J.; Zhang, H.; Xu, L.; Chen, Y. Proprotein convertase subtilisn/kexin type 9 (PCSK9) in lipid metabolism, atherosclerosis and ischemic stroke. Int. J. Neurosci. 2015, 126, 675–680. [Google Scholar]
- Burnap, S.A.; Sattler, K.; Pechlaner, R.; Duregotti, E.; Lu, R.; Theofilatos, K.; Takov, K.; Heusch, G.; Tsimikas, S.; Fernández-Hernando, C.; et al. PCSK9 Activity is Potentiated Through HDL Binding. Circ. Res. 2021, 129, 1039–1053. [Google Scholar] [CrossRef] [PubMed]
- Denis, M.; Marcinkiewicz, J.; Zaid, A.; Gauthier, D.; Poirier, S.; Lazure, C.; Seidah, N.G.; Prat, A. Gene inactivation of proprotein convertase subtilisin/kexin type 9 reduces atherosclerosis in mice. Circulation 2012, 125, 894–901. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ding, Z.; Pothineni, N.V.K.; Goel, A.; Lüscher, T.F.; Mehta, J.L. PCSK9 and Inflammation: Role of shear stress, pro-inflammatory cytokine, and LOX-1. Cardiovasc. Res. 2020, 116, 908–915. [Google Scholar] [CrossRef] [PubMed]
- Charan Reddy, K.V. Heart-gut axis: Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) to prevent cardiovascular disease through gut microbiota. Med. Microecol. 2021, 7, 100033. [Google Scholar] [CrossRef]
- Yingling, L.R.; Mitchell, V.; Ayers, C.R.; Peters-Lawrence, M.; Wallen, G.R.; Brooks, A.T.; Troendle, J.F.; Adu-Brimpong, J.; Thomas, S.; Henry, J.; et al. Adherence with physical activity monitoring wearable devices in a community-based population: Observations from the Washington, D.C.; Cardiovascular Health and Needs Assessment. Transl. Behav. Med. 2017, 7, 719–730. [Google Scholar] [CrossRef] [Green Version]
- Goff, D.C., Jr.; Lloyd-Jones, D.M.; Bennett, G.; Coady, S.; D’Agostino, R.B.; Gibbons, R.; Greenland, P.; Lackland, D.T.; Levy, D.; O’Donnell, C.J.; et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014, 129, S49–S73. [Google Scholar] [CrossRef] [Green Version]
- Farmer, N.; Gutierrez-Huerta, C.A.; Turner, B.S.; Mitchell, V.M.; Collins, B.S.; Baumer, Y.; Wallen, G.R.; Powell-Wiley, T.M. Neighborhood Environment Associates with Trimethylamine-N-Oxide (TMAO) as a Cardiovascular Risk Marker. Int. J. Environ. Res. Public Health 2021, 18, 4296. [Google Scholar] [CrossRef]
- Fu, B.C.; Hullar, M.A.J.; Randolph, T.W.; Franke, A.A.; Monroe, K.R.; Cheng, I.; Wilkens, L.R.; Shepherd, J.A.; Madeleine, M.M.; Le Marchand, L.; et al. Associations of plasma trimethylamine N-oxide, choline, carnitine, and betaine with inflammatory and cardiometabolic risk biomarkers and the fecal microbiome in the Multiethnic Cohort Adiposity Phenotype Study. Am. J. Clin. Nutr. 2020, 111, 1226–1234. [Google Scholar] [CrossRef]
- Patel, V.C.; White, H.; Støy, S.; Bajaj, J.S.; Shawcross, D.L. Clinical science workshop: Targeting the gut-liver-brain axis. Metab. Brain Dis. 2016, 31, 1327–1337. [Google Scholar] [CrossRef] [Green Version]
- Zhang, X.; Li, Y.; Yang, P.; Liu, X.; Lu, L.; Chen, Y.; Zhong, X.; Li, Z.; Liu, H.; Ou, C.; et al. Trimethylamine-N-Oxide Promotes Vascular Calcification Through Activation of NLRP3 (Nucleotide-Binding Domain, Leucine-Rich-Containing Family, Pyrin Domain-Containing-3) Inflammasome and NF-κB (Nuclear Factor κB) Signals. Arterioscler. Thromb. Vasc. Biol. 2020, 40, 751–765. [Google Scholar] [CrossRef]
- Momtazi-Borojeni, A.A.; Sabouri-Rad, S.; Gotto, A.M., Jr.; Pirro, M.; Banach, M.; Awan, Z.; Barreto, G.E.; Sahebkar, A. PCSK9 and inflammation: A review of experimental and clinical evidence. Eur. Heart J.-Cardiovasc. Pharmacother. 2019, 5, 237–245. [Google Scholar] [CrossRef] [PubMed]
- Ding, Z.; Wang, X.; Liu, S.; Zhou, S.; Kore, R.A.; Mu, S.; Deng, X.; Fan, Y.; Mehta, J.L. NLRP3 inflammasome via IL-1β regulates PCSK9 secretion. Theranostics 2020, 10, 7100–7110. [Google Scholar] [CrossRef] [PubMed]
- Liu, S.; Deng, X.; Zhang, P.; Wang, X.; Fan, Y.; Zhou, S.; Mu, S.; Mehta, J.L.; Ding, Z. Blood flow patterns regulate PCSK9 secretion via MyD88-mediated pro-inflammatory cytokines. Cardiovasc. Res. 2020, 116, 1721–1732. [Google Scholar] [CrossRef] [PubMed]
- Apostolakis, S.; Vogiatzi, K.; Amantidou, V.; Spandidos, D.A. Interleukin 8 and cardiovascular disease. Cardiovasc. Res. 2009, 84, 353–360. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Meniailo, M.E.; Malashchenko, V.V.; Shmarov, V.A.; Gazatova, N.D.; Melashchenko, O.B.; Goncharov, A.G.; Seledtsova, G.V.; Seledtsov, V.I. Interleukin-8 favors pro-inflammatory activity of human monocytes/macrophages. Int. Immunopharmacol. 2018, 56, 217–221. [Google Scholar] [CrossRef] [PubMed]
- Hakhamaneshi, M.S.; Abdolahi, A.; Vahabzadeh, Z.; Abdi, M.; Andalibi, P. Toll-Like Receptor 4: A Macrophage Cell Surface Receptor Is Activated By Trimethylamine-N-Oxide. Cell J. 2021, 23, 516–522. [Google Scholar] [PubMed]
- Montefusco, L.; D’Addio, F.; Loretelli, C.; Ben Nasr, M.; Garziano, M.; Rossi, A.; Pastore, I.; Plebani, L.; Lunati, M.E.; Bolla, A.M.; et al. Anti-Inflammatory effects of diet and caloric restriction in metabolic syndrome. J. Endocrinol. Investig. 2021, 44, 2407–2415. [Google Scholar] [CrossRef]
- Shapiro, M.D.; Tavori, H.; Fazio, S. PCSK9 from Basic Science Discoveries to Clinical Trials. Circ. Res. 2018, 122, 1420–1438. [Google Scholar] [CrossRef]
- Clark, A.M.; Desmeules, M.; Luo, W.; Duncan, A.S.; Wielgosz, A. Socioeconomic status and cardiovascular disease: Risks and implications for care. Nat. Rev. Cardiol. 2009, 6, 712–722. [Google Scholar] [CrossRef]
Mean (SD)/Total n (%) | |
---|---|
African American | 60 (100) |
Sex, Female | 56 (93.33) |
Age (years) | 60.83 ± 10.52 |
Type 2 Diabetes Mellitus History | 13 (21.67) |
Hyperlipidemia History | 33 (55.00) |
Smoking History | 7 (11.67) |
BMI (kg/m2) | 33.00 ± 7.85 |
LDL (mg/dL) | 105.5 ± 33.02 |
HDL (mg/dL) | 66.57 ± 20.58 |
Triglycerides (mg/dL) | 84.97 ± 26.43 |
Total Cholesterol (mg/dL) | 188.98 ± 35.20 |
TMAO (ng/mL) | 37.54 ± 72.61 |
PCSK9 (ng/mL) | 326.52 ± 83.66 |
ASCVD 10-Year Risk Score * (%) | 10.75 ± 8.51 |
IL-8 (pg/mL) | 4.54 (2.63–5.37) ** |
IFNγ (pg/mL) | 8.83 (3.37–10.01) ** |
IL-18 (pg/mL) | 399.998 (265.78–496.29) |
IL-1β (pg/mL) | 0.19 (0.10–0.22) ** |
TNFα (pg/mL) | 1.61 (1.25–1.88) ** |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Baginski, A.M.; Farmer, N.; Baumer, Y.; Wallen, G.R.; Powell-Wiley, T.M. Interleukin-8 (IL-8) as a Potential Mediator of an Association between Trimethylamine N-Oxide (TMAO) and Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) among African Americans at Risk of Cardiovascular Disease. Metabolites 2022, 12, 1196. https://doi.org/10.3390/metabo12121196
Baginski AM, Farmer N, Baumer Y, Wallen GR, Powell-Wiley TM. Interleukin-8 (IL-8) as a Potential Mediator of an Association between Trimethylamine N-Oxide (TMAO) and Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) among African Americans at Risk of Cardiovascular Disease. Metabolites. 2022; 12(12):1196. https://doi.org/10.3390/metabo12121196
Chicago/Turabian StyleBaginski, Alyssa M., Nicole Farmer, Yvonne Baumer, Gwenyth R. Wallen, and Tiffany M. Powell-Wiley. 2022. "Interleukin-8 (IL-8) as a Potential Mediator of an Association between Trimethylamine N-Oxide (TMAO) and Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) among African Americans at Risk of Cardiovascular Disease" Metabolites 12, no. 12: 1196. https://doi.org/10.3390/metabo12121196